()

HCPCS code G2070: Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or  administration,  substance  use counseling, individual  and group therapy, and toxicology testing if performed (provision of the services by a Medicare -enrolled Opioid Treatment Program).   HCPCS code G2071: Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or  administration,  substance  use counseling, individual  and group therapy, and toxicology testing if performed (provision of the services by a Medicare -enrolled Opioid Treatment Program).   HCPCS  code  G2072:  Medication  assisted  treatment,  buprenorphine  (implant insertion  and removal);  weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare -enrolled Opioid Treatment Program).   HCPCS  code  G2073:  Medication  assisted  treatment,  naltrexone;  weekly  bundle  including dispensing  and/or administration, substance use  counseling, individual and group therapy, and toxicology testing  if performed (provision of the services by a Medicare- enrolled Opioid Treatment Program).   HCPCS code G2074: Medication assisted treatment, weekly bundle not including the drug, including substance  use counseling, individual  and group therapy,  and toxicology testing  if performed  (provision of the services by a Medicare -enrolled Opioid Treatment Program).   HCPCS code  G2075: Medication assisted treatment, medication not otherwise  specified; weekly  bundle including dispensing and/or  administration,  substance  use counseling, individual  and group therapy, and toxicology testing, if performed (provision of the services by a Medicare -enrolled Opioid Treatment Program).   HCPCS code G2076: Intake activities, including initial medical examination that is a complete, fully documented physical evaluation and initial assessment conducted by a program physician or a primary care physician,  or an authorized  healthcare  professional  under  the supervision of a program  physician or qualified personnel that includes preparation of a treatment plan that includes the patients short -term goals and the tasks the patient must perform to complete the short -term goals; the patients requirements for education, vocational rehabilitation, and employment; and the medical, psycho-  social, economic, legal, or other  supportive services that a patient needs, conducted by qualified personnel (provision of the services by a Medicare -enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.   HCPCS code G2077: Periodic assessment; assessing periodically  by qualified personnel to determine the most  appropriate  combination of services  and treatment  (provision of the services  by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.   HCPCS code G2078: Take -home supply of methadone; up to 7 additional day supply (provision of the services  by a Medicare- enrolled Opioid Treatment Program); List separately  in addition to code  for primary procedure.   HCPCS  code  G2079:  Take- home  supply of buprenorphine  (oral);  up to  7 additional  day supply (provision of the services by a Medicare- enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.   HCPCS  code  G2080:  Each  additional  30 minutes  of counseling or group or individual  therapy  in a week  of medication assisted treatment, (provision of the services by a Medicare -enrolled Opioid Treatment  Program);  List separately  in addition to  code  for primary  procedure.   HCPCS code G2215: Take- home supply of nasal naloxone; 2- pack of 4mg per 0.1 mL nasal spray (provision of the services by  a Medicare- enrolled Opioid Treatment  Program); List separately  in addition to code for primary procedure.  HCPCS  code  G2216:  Take- home  supply of injectable naloxone  (provision of  the services  by a Medicare - enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.  HCPCS code G1028: Take -home supply of nasal naloxone; 2- pack of 8mg per 0.1 mL nasal spray (provision of the services by  a Medicare- enrolled Opioid Treatment  Program); List separately  in addition to code for primary procedure.   HCPCS code G0137:  Intensive outpatient services; minimum of nine services over a 7 - contiguous day period, which can include individual and group therapy with physicians or psychologists (or other mental health professionals to the extent authorized under State law); occupational therapy requiring the skills of a qualified occupational therapist; services of social  workers, trained psychiatric nurses, and other staff trained to work with psychiatric patients; drugs and biologicals furnished for therapeutic purposes, excluding opioid agonist and antagonist medications that are FDA -approved for use in treatment of OUD or opioid antagonist medications for the emergency treatment of known or suspected opioid overdose; individualized activity therapies that are not primarily recreational or diversionary; family counseling (the primary purpose of which is treatment of the indivi duals condition); patient training and education (to the extent that training and educational activities are closely and clearly related to individuals care and treatment); diagnostic services (not including toxicology testing); (provision of the service s by a Medicare- enrolled Opioid Treatment Program); List separately in addition to code for primary procedure, if applicable .  Only  an entity  enrolled  with Medicare as an OTP  can bill these codes.  OTPs are limited  to billing  only these codes  describing  bundled payments,  and may not bill  for other  codes,  such as  those  paid under  the Medicare Physician Fee Schedule (PFS).   F. Payment  Rates  The codes describing the OTP bundled services (HCPCS codes G2067- G2075) are assigned flat dollar payment amounts. The payment rates for OUD treatment services are derived by combining the cost of the drug and the non-drug components  (as applicable)  into a single  bundled payment  as described  in more  detail below.   1. Drug  component   As part of determining a payment rate for the bundles for OUD treatment services, a dosage of the applicable medication  was selected  in order  to calculate  the cost of the drug component  of the bundle.  In order  to determine  the drug costs  for the weekly  bundles, the following typical  or average maintenance dosages were used:    a 100 mg daily  dose for methadone,   a 16 mg daily  dose for oral buprenorphine   a 100 mg monthly dose for the extended -release  buprenorphine  injection,   four rods each containing  74.2 mg of buprenorphine  for the  6-month buprenorphine  implant, and   a 380 mg monthly dose for extended -release injectable  naltrexone)   Nasal naloxone is supplied as a single -dose intranasal spray containing 2mg, 4mg, or 8mg of naloxone hydrochloride  in 0.1mL.3 Nasal  naloxone  is packaged  in a carton  containing two doses  to allow  for repeat dosing if needed.   Effective January  1, 2021, injectable  naloxone  is contractor  priced. CMS  may establish  national  pricing for injectable naloxone through future rulemaking. According to the package insert45, an initial dose of 0.4 mg to 2 mg of injectable naloxone may be administered through intravenous, intramuscular, or subcutaneous routes. If needed, it may be repeated at two - to three -minute intervals up to a total dose of 10mg.  Drug  Pricing  Data  Source  For Part B  drugs, use the methodology in section  1847A  of the Act (which bases  most  payments  on average sales price (ASP)) to set the payment rates for the incident to drugs and limit the payment amounts for these  drugs  to 100 percent  of the volume -weighted ASP  for a drug category  or code,  and beginning January 1, 2021, the payment must be 100 percent of wholesale acquisition cost (WAC), if WAC is used.   For oral drugs, use ASP -based payment to set the payment rates for the oral product categories when CMS receives manufacturer -submitted ASP data for these drugs and limit the payment amounts for oral drugs to 100 percent  of the volume -weighted  ASP.  When ASP  data are not available for the oral drugs  used in OTPs, use the National Average Drug Acquisition Cost (NADAC) data to set the payment for the drug component of the oral buprenorphine bundle.   For CY 2022, CMS  established  a limited  exception  to the current  methodology for determining  the payment amount for the drug component of an episode of care in order to freeze the payment amount for methadone furnished during an episode of care in CY 2022 at the payment amount that was determined for CY 2021.   Beginning January 1, 2023, the methodology for pricing the drug component of the methadone weekly bundle  and the  add-on code  for take -home  supplies of methadone  will be  based on and updated annually by the  Producer  Price Index (PPI) for Pharmaceuticals  for Human  Use (Prescription).  The TRICARE  rate will no longer be an alternative pricing methodology for methadone after January 1, 2023.  2. Non-drug  component   The payment  rate for the non-drug component  is calculated  based  on a building block methodology using the Medicare payment rates for similar services furnished in the non -facility setting. Additionally, the non-drug component  rate is adjusted  to account  for different  administration  and dispensing costs of the drug that is used in the episode of care (either oral, injectable, or implantable. The rate for dispensing oral drugs is determined using an approximation of the average dispensing fees under state Medicaid programs, which is $10.50, since there is no Medicare Part B rate for oral MAT drugs. The payment for the non- drug component of weekly bundles that include injectable drugs (buprenorphine and naltrexone) will include the Medicare non- facility rate for administration of an injection.  Medication  not otherwise specified    The payment for the non- drug component of the medication not otherwise specified bundle is based on whether the drug is oral, injectable, or implantable. This payment uses the building block payment methodology to determine  the non-drug component  of the bundled payments  for medications  that have  the same mode of administration.   3. Place of Service (POS) Code  for Services Furnished at  OTPs   POS code  specific to OTPs  was created  since  there were no existing POS codes  that specifically  describe OTPs:    Place of Service  code 58 (Non -residential  Opioid Treatment  Facility a location  that provides  treatment for OUD on an ambulatory basis. Services include methadone and other forms of MAT).   CMS expects that POS code 58 will be noted on claims submitted for the HCPCS G codes describing OTP services. Additionally, the G codes describing the OTP bundled payments and add- on codes can only be billed by OTPs  and cannot  be billed  by other  providers. POS  codes  are not limited  to Medicare use and may be used by other payers.  In regards to non- OTP pharmacies dispensing MAT drugs included in an OTP bundle, CMS encourages pharmacies  and prescribing OTPs  to be in close communication  in order  to ensure  proper  billing  procedures are followed and to prevent duplicative payments. The presence of POS code 58 on retail pharmacy claims will not mean that the pharmacy should process MAT claims any differently than they do now.  3 https://www.narcan.com/static/Gen2 -Prescribing -Information.pdf  4 http://labeling.pfizer.com/ShowLabeling.aspx?id=4541 5 https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f0932877- 1f3b- 4d5e -82d2- dd6c53db4730&type=display.      40.1.2 - Duplicative Payments Under Parts B or D  (Rev. 11219; Issued: 01- 27-22; Effective: 01 -01-22; Implementation: 03 -01-22)   Section 1834(w)(1) of the Act, added by section 2005(c) of the SUPPORT Act, requires the Secretary to ensure, as determined appropriate by the Secretary, that no duplicative payments are made under Part B or Part D for items and services furnished by an OT P.